Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Naomi Abe , John D Bisognano Added: 3 years ago
Hypertension is the most common chronic disease in the US, affecting 29% of the adult population.1 Once considered a benign, compensatory mechanism for ageing, high blood pressure (BP) is now recognised as an important risk factor for cardiovascular disease. It is estimated that inadequate BP control is responsible for 62% of cases of cerebrovascular disease, 49% of cases of ischemic heart… View more

Prevention & Chronic Conditions
Author(s): George Thomas , Emmanuel L Bravo Added: 3 years ago
Distinct hypertensive syndromes causing drug-resistant hypertension are increasingly being recognised. The ability to recognise these disorders has come as a result of a better understanding of their pathogenesis and the availability of sensitive and accurate diagnostic tools. The particular appeal of making the diagnosis centres around the potential curability of the hypertension, with… View more

Prevention & Chronic Conditions
Author(s): Domenic A Sica Added: 3 years ago
Hypertension is a major cause of morbidity and mortality worldwide.1–3 In the US, around 25% of the adult population has a blood pressure (BP) of ≥140/90mmHg, which is the defined cut-off value for hypertension.3 Although there are many effective pharmacotherapies available, many patients are not adequately controlled on their current antihypertensive regimens. The National Health and Nutrition… View more

Prevention & Chronic Conditions
Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure
Author(s): Deepak L Bhatt , Anna Meta Dyrvig Kristensen , Manan Pareek , et al Added: 3 years ago
Hypertension is an important contributor to global morbidity and mortality and is a major burden on healthcare systems.1,2 More than 20% of the world’s population has high blood pressure when defined by conventional criteria: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.3,4 Even with therapeutic lifestyle and pharmacological measures, blood pressure remains poorly… View more

Heart Failure

Prevention & Chronic Conditions
AHA 22: PRECISION: Aprocitentan in the Treatment of Resistant Hypertension
Author(s): Markus P Schlaich Added: 1 year ago
AHA 2022 — Dr Markus P Schlaich (University of Western Australia, AU) joins us to discuss the key findings from the PRECISION trial (NCT03541174).This randomized, phase 3 study assessed the sustained blood pressure lowering effect of a dual endothelin receptor antagonist, aprocitentan (Idorsia Pharmaceuticals Ltd.) in resistant hypertension. Presented first at AHA 22, the trial showed that… View more

Prevention & Chronic Conditions
RADIANCE-HTN: 6Mo Outcomes of RDN Vs a Sham Procedure for Resistant Hypert
Author(s): Ajay J Kirtane Added: 2 years ago
In this short summary interview, Dr. Ajay Kirtane (Columbia University Medical Center, US) shares the six-month outcomes of a randomized trial of renal denervation (RDN) versus a sham procedure for resistant hypertension. The RADIANCE-TRIO Trial, presented first at TCT 2021, showed that the additional effects of pharmacologic intervention with maintenance of a BP-lowering effect of endovascular… View more

Intervention
Renal Denervation Benefit Patients with Hypertension
Author(s): Andrew SP Sharp , Indranil Dasgupta , Felix Mahfoud , et al Start date: Dec 07, 2018

Prevention & Chronic Conditions

Intervention
View from the Thoraxcenter: AHA 22 Late-breaking Science Wrap-up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
Stay updated on the AHA 22 late-breaking data! In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions. What are the key take-aways from AHA 22? What are the most promising findings? How should we understand… View more

Standards & Guidelines

Heart Failure
Professor Melvin Lobo is a Consultant Physician based in St Bartholomew’s Hospital and the William Harvey Research Institute. He has a specialist interest in blood pressure disorders of all types, autonomic control of the circulation and also resistant hypertension and device-based therapies. View more
Dr Indranil Dasgupta
Dr Indranil Dasgupta is a Consultant Nephrologist at Heart of England NHS Foundation Trust, and is an Honorary Senior Lecturer at the University of Birmingham, UK. His research interests include treatment resistant hypertension. Dr Dasgupta is Clinical Research Lead Division 2 for Renal, Stroke, CVD, Diabetes and Metabolic Diseases for the West Midlands in NIHR Clinical Research Network, Honorary… View more